# Immunogenicity of Influenza Vaccinations

> **NCT06518577** · PHASE4 · COMPLETED · sponsor: **Duke University** · enrollment: 605 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flucelvax (ccIIV4)
- **BIOLOGICAL:** Flublok (RIV) or Fluzone (IIV)

## Key facts

- **NCT ID:** NCT06518577
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-09
- **Primary completion:** 2024-12-09
- **Final completion:** 2025-06-04
- **Target enrollment:** 605 (ACTUAL)
- **Last updated:** 2025-06-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06518577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06518577, "Immunogenicity of Influenza Vaccinations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06518577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*